Pfizer's Ibrance Shows Promise in Treating Metastatic Breast Cancer

Pfizer ($PFE (+1,49%)) announced positive Phase 3 trial results for its drug Ibrance in combination with standard therapies for HR+, HER2+ metastatic breast cancer.

The PATINA study revealed that patients receiving Ibrance alongside anti-HER2 and endocrine therapies experienced a median progression-free survival (PFS) of 44.3 months, compared to 29.1 months with standard therapies alone.

While overall survival data is still pending, these findings were presented at the San Antonio Breast Cancer Symposium. Ibrance is already approved for treating HR+, HER2- advanced or metastatic breast cancer in combination with other therapies.